Trial Outcomes & Findings for The PEERLESS Study (NCT NCT05111613)

Last Updated: 2025-11-13

Results Overview

The primary endpoint is a composite constructed as a hierarchical win ratio of the following 5 components: 1. All-cause mortality, or 2. Intracranial hemorrhage (ICH), or 3. Major bleeding per ISTH definition, or 4. Clinical deterioration defined by hemodynamic or respiratory worsening, and/or escalation to a bailout therapy, or 5. ICU admission and ICU length-of-stay during the index hospitalization and following the index procedure. A win ratio larger than 1 indicates that patients who receive treatment with FlowTriever are more likely to have better outcomes as compared to subjects treated with CDT.

Recruitment status

COMPLETED

Study phase

Target enrollment

692 participants

Primary outcome timeframe

Hospital discharge or at 7 days after the index procedure, whichever is sooner

Results posted on

2025-11-13

Participant Flow

Participant milestones

Participant milestones
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system)	Non-Randomized Contraindication to Thrombolytics Cohort Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
Overall Study STARTED	276	142	274
Overall Study COMPLETED	255	126	261
Overall Study NOT COMPLETED	21	16	13

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Subject reported ethnicity was unavailable in 25 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 26 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 20 subjects in the non-randomized cohort.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Randomized Controlled Trial Cohort - FlowTriever Arm n=274 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=276 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=142 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Total n=692 Participants Total of all reporting groups
Age, Continuous	63.7 years STANDARD_DEVIATION 13.0 • n=274 Participants	61.2 years STANDARD_DEVIATION 14.8 • n=276 Participants	64.3 years STANDARD_DEVIATION 13.9 • n=142 Participants	62.8 years STANDARD_DEVIATION 14.0 • n=692 Participants
Sex: Female, Male Female	125 Participants n=274 Participants	134 Participants n=276 Participants	64 Participants n=142 Participants	323 Participants n=692 Participants
Sex: Female, Male Male	149 Participants n=274 Participants	142 Participants n=276 Participants	78 Participants n=142 Participants	369 Participants n=692 Participants
Race/Ethnicity, Customized White	184 Participants n=274 Participants	193 Participants n=276 Participants	91 Participants n=142 Participants	468 Participants n=692 Participants
Race/Ethnicity, Customized Black or African American	67 Participants n=274 Participants	56 Participants n=276 Participants	24 Participants n=142 Participants	147 Participants n=692 Participants
Race/Ethnicity, Customized Other/multiple	3 Participants n=274 Participants	7 Participants n=276 Participants	4 Participants n=142 Participants	14 Participants n=692 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	0 Participants n=274 Participants	0 Participants n=276 Participants	2 Participants n=142 Participants	2 Participants n=692 Participants
Race/Ethnicity, Customized Asian	0 Participants n=274 Participants	3 Participants n=276 Participants	1 Participants n=142 Participants	4 Participants n=692 Participants
Race/Ethnicity, Customized Unavailable	20 Participants n=274 Participants	17 Participants n=276 Participants	20 Participants n=142 Participants	57 Participants n=692 Participants
Race/Ethnicity, Customized Hispanic or Latino	13 Participants n=249 Participants • Subject reported ethnicity was unavailable in 25 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 26 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 20 subjects in the non-randomized cohort.	27 Participants n=250 Participants • Subject reported ethnicity was unavailable in 25 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 26 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 20 subjects in the non-randomized cohort.	21 Participants n=122 Participants • Subject reported ethnicity was unavailable in 25 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 26 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 20 subjects in the non-randomized cohort.	61 Participants n=621 Participants • Subject reported ethnicity was unavailable in 25 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 26 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 20 subjects in the non-randomized cohort.
Renal dysfunction (CrCL 30-60 mL/min)	43 Participants n=274 Participants	45 Participants n=276 Participants	33 Participants n=142 Participants	121 Participants n=692 Participants
Body Mass Index	34.5 kg/m^2 STANDARD_DEVIATION 8.6 • n=274 Participants • Data missing for one subject in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm and one subject in the non-randomized cohort.	36.3 kg/m^2 STANDARD_DEVIATION 9.4 • n=275 Participants • Data missing for one subject in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm and one subject in the non-randomized cohort.	32.0 kg/m^2 STANDARD_DEVIATION 6.7 • n=141 Participants • Data missing for one subject in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm and one subject in the non-randomized cohort.	34.7 kg/m^2 STANDARD_DEVIATION 8.7 • n=690 Participants • Data missing for one subject in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm and one subject in the non-randomized cohort.
History of cancer	56 Participants n=274 Participants	56 Participants n=276 Participants	51 Participants n=142 Participants	163 Participants n=692 Participants
Active cancer	13 Participants n=274 Participants	17 Participants n=276 Participants	39 Participants n=142 Participants	69 Participants n=692 Participants
Prior pulmonary embolism	41 Participants n=274 Participants	31 Participants n=276 Participants	12 Participants n=142 Participants	84 Participants n=692 Participants
History of pulmonary hypertension	6 Participants n=274 Participants	5 Participants n=276 Participants	7 Participants n=142 Participants	18 Participants n=692 Participants
Prior deep vein thrombosis	60 Participants n=274 Participants	58 Participants n=276 Participants	25 Participants n=142 Participants	143 Participants n=692 Participants
Concomitant deep vein thrombosis	178 Participants n=274 Participants	168 Participants n=276 Participants	90 Participants n=142 Participants	436 Participants n=692 Participants
History of bleeding	5 Participants n=274 Participants	9 Participants n=276 Participants	31 Participants n=142 Participants	45 Participants n=692 Participants
Active bleeding preprocedure	0 Participants n=274 Participants	2 Participants n=276 Participants	12 Participants n=142 Participants	14 Participants n=692 Participants
Anemia	21 Participants n=274 Participants	27 Participants n=276 Participants	47 Participants n=142 Participants	95 Participants n=692 Participants
History of renal disease	28 Participants n=274 Participants	33 Participants n=276 Participants	29 Participants n=142 Participants	90 Participants n=692 Participants
Recent surgery (within 3 weeks)	22 Participants n=274 Participants	12 Participants n=276 Participants	48 Participants n=142 Participants	82 Participants n=692 Participants
Recent trauma (within 3 weeks)	8 Participants n=274 Participants	7 Participants n=276 Participants	18 Participants n=142 Participants	33 Participants n=692 Participants
Prior cerebrovascular accident	7 Participants n=274 Participants	8 Participants n=276 Participants	17 Participants n=142 Participants	32 Participants n=692 Participants
Relative contraindication to thrombolytics Total	12 Participants n=274 Participants • Data for this Baseline Measure were only collected for participants in the Randomized Controlled Trial Cohorts and were not available for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort.	11 Participants n=276 Participants • Data for this Baseline Measure were only collected for participants in the Randomized Controlled Trial Cohorts and were not available for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort.	0 Participants Data for this Baseline Measure were only collected for participants in the Randomized Controlled Trial Cohorts and were not available for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort.	23 Participants n=550 Participants • Data for this Baseline Measure were only collected for participants in the Randomized Controlled Trial Cohorts and were not available for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort.
Relative contraindication to thrombolytics Anemia (hemoglobin <10 g/dL)	3 Participants n=274 Participants • Data for this Baseline Measure were only collected for participants in the Randomized Controlled Trial Cohorts and were not available for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort.	5 Participants n=276 Participants • Data for this Baseline Measure were only collected for participants in the Randomized Controlled Trial Cohorts and were not available for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort.	0 Participants Data for this Baseline Measure were only collected for participants in the Randomized Controlled Trial Cohorts and were not available for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort.	8 Participants n=550 Participants • Data for this Baseline Measure were only collected for participants in the Randomized Controlled Trial Cohorts and were not available for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort.
Relative contraindication to thrombolytics Oral anticoagulation, except for aspirin	4 Participants n=274 Participants • Data for this Baseline Measure were only collected for participants in the Randomized Controlled Trial Cohorts and were not available for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort.	3 Participants n=276 Participants • Data for this Baseline Measure were only collected for participants in the Randomized Controlled Trial Cohorts and were not available for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort.	0 Participants Data for this Baseline Measure were only collected for participants in the Randomized Controlled Trial Cohorts and were not available for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort.	7 Participants n=550 Participants • Data for this Baseline Measure were only collected for participants in the Randomized Controlled Trial Cohorts and were not available for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort.
Relative contraindication to thrombolytics Therapeutic LMWH within 24 hours	4 Participants n=274 Participants • Data for this Baseline Measure were only collected for participants in the Randomized Controlled Trial Cohorts and were not available for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort.	2 Participants n=276 Participants • Data for this Baseline Measure were only collected for participants in the Randomized Controlled Trial Cohorts and were not available for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort.	0 Participants Data for this Baseline Measure were only collected for participants in the Randomized Controlled Trial Cohorts and were not available for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort.	6 Participants n=550 Participants • Data for this Baseline Measure were only collected for participants in the Randomized Controlled Trial Cohorts and were not available for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort.
Relative contraindication to thrombolytics Refractory hypertension (SBP >180 mmHg or DBP >110 mmHg on two confirmed measurements	1 Participants n=274 Participants • Data for this Baseline Measure were only collected for participants in the Randomized Controlled Trial Cohorts and were not available for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort.	2 Participants n=276 Participants • Data for this Baseline Measure were only collected for participants in the Randomized Controlled Trial Cohorts and were not available for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort.	0 Participants Data for this Baseline Measure were only collected for participants in the Randomized Controlled Trial Cohorts and were not available for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort.	3 Participants n=550 Participants • Data for this Baseline Measure were only collected for participants in the Randomized Controlled Trial Cohorts and were not available for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort.
Absolute contraindication to thrombolytics Total	0 Participants Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	0 Participants Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	142 Participants n=142 Participants • Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	142 Participants n=142 Participants • Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.
Absolute contraindication to thrombolytics Any other condition on the product label for use by local standard and investigator discretion	0 Participants Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	0 Participants Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	62 Participants n=142 Participants • Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	62 Participants n=142 Participants • Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.
Absolute contraindication to thrombolytics Recent (3 months) intracranial or intraspinal surgery or serious head trauma	0 Participants Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	0 Participants Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	32 Participants n=142 Participants • Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	32 Participants n=142 Participants • Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.
Absolute contraindication to thrombolytics Presence of intracranial conditions such as neoplasms, arteriovenous malformations, or aneurysms	0 Participants Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	0 Participants Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	24 Participants n=142 Participants • Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	24 Participants n=142 Participants • Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.
Absolute contraindication to thrombolytics Active internal bleeding, excluding menses	0 Participants Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	0 Participants Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	12 Participants n=142 Participants • Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	12 Participants n=142 Participants • Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.
sPESI score Score >=1	203 Participants n=273 Participants • Data unavailable in 1 subject in the Randomized Controlled Trial Cohort - FlowTriever Arm.	213 Participants n=276 Participants • Data unavailable in 1 subject in the Randomized Controlled Trial Cohort - FlowTriever Arm.	128 Participants n=142 Participants • Data unavailable in 1 subject in the Randomized Controlled Trial Cohort - FlowTriever Arm.	544 Participants n=691 Participants • Data unavailable in 1 subject in the Randomized Controlled Trial Cohort - FlowTriever Arm.
Absolute contraindication to thrombolytics History of hemorrhagic stroke or stroke of unknown origin	0 Participants Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	0 Participants Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	10 Participants n=142 Participants • Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	10 Participants n=142 Participants • Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.
Absolute contraindication to thrombolytics Bleeding diathesis	0 Participants Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	0 Participants Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	10 Participants n=142 Participants • Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	10 Participants n=142 Participants • Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.
Absolute contraindication to thrombolytics Severe uncontrolled hypertension	0 Participants Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	0 Participants Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	5 Participants n=142 Participants • Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	5 Participants n=142 Participants • Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.
Absolute contraindication to thrombolytics Ischemic stroke in the previous 6 months	0 Participants Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	0 Participants Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	4 Participants n=142 Participants • Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	4 Participants n=142 Participants • Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.
Absolute contraindication to thrombolytics Aortic dissection	0 Participants Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	0 Participants Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	2 Participants n=142 Participants • Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.	2 Participants n=142 Participants • Data for this Baseline Measure were only collected for participants in the Non-Randomized Absolute Contraindication to Thrombolytics Cohort and were not available for participants in the Randomized Controlled Trial Cohorts.
VTE-BLEED score	1.55 units on a scale STANDARD_DEVIATION 1.30 • n=274 Participants	1.56 units on a scale STANDARD_DEVIATION 1.31 • n=276 Participants	2.77 units on a scale STANDARD_DEVIATION 1.78 • n=142 Participants	1.8 units on a scale STANDARD_DEVIATION 1.49 • n=692 Participants
VTE-BLEED score Score >=2	68 Participants n=274 Participants	77 Participants n=276 Participants	81 Participants n=142 Participants	226 Participants n=692 Participants
VTE-BLEED score Score <2	206 Participants n=274 Participants	199 Participants n=276 Participants	61 Participants n=142 Participants	466 Participants n=692 Participants
sPESI score	1.3 units on a scale STANDARD_DEVIATION 1.1 • n=273 Participants • Data unavailable in 1 subject in the Randomized Controlled Trial Cohort - FlowTriever Arm.	1.3 units on a scale STANDARD_DEVIATION 1.1 • n=276 Participants • Data unavailable in 1 subject in the Randomized Controlled Trial Cohort - FlowTriever Arm.	1.7 units on a scale STANDARD_DEVIATION 1.1 • n=142 Participants • Data unavailable in 1 subject in the Randomized Controlled Trial Cohort - FlowTriever Arm.	1.4 units on a scale STANDARD_DEVIATION 1.1 • n=691 Participants • Data unavailable in 1 subject in the Randomized Controlled Trial Cohort - FlowTriever Arm.
Most central PE location at screening Main pulmonary artery	143 Participants n=274 Participants	143 Participants n=276 Participants	76 Participants n=142 Participants	362 Participants n=692 Participants
sPESI score Score =0	70 Participants n=273 Participants • Data unavailable in 1 subject in the Randomized Controlled Trial Cohort - FlowTriever Arm.	63 Participants n=276 Participants • Data unavailable in 1 subject in the Randomized Controlled Trial Cohort - FlowTriever Arm.	14 Participants n=142 Participants • Data unavailable in 1 subject in the Randomized Controlled Trial Cohort - FlowTriever Arm.	147 Participants n=691 Participants • Data unavailable in 1 subject in the Randomized Controlled Trial Cohort - FlowTriever Arm.
Intermediate risk PE Intermediate-high-risk PE	256 Participants n=274 Participants	265 Participants n=276 Participants	128 Participants n=142 Participants	649 Participants n=692 Participants
Intermediate risk PE Intermediate-low-risk PE	18 Participants n=274 Participants	11 Participants n=276 Participants	14 Participants n=142 Participants	43 Participants n=692 Participants
Duration of symptoms, days	2.9 days STANDARD_DEVIATION 2.8 • n=274 Participants	3.5 days STANDARD_DEVIATION 3.3 • n=276 Participants	2.8 days STANDARD_DEVIATION 2.8 • n=142 Participants	3.1 days STANDARD_DEVIATION 3.0 • n=692 Participants
Elevated cardiac troponin levels	256 Participants n=274 Participants	265 Participants n=276 Participants	128 Participants n=142 Participants	649 Participants n=692 Participants
Most central PE location at screening Saddle	104 Participants n=274 Participants	109 Participants n=276 Participants	58 Participants n=142 Participants	271 Participants n=692 Participants
Most central PE location at screening Lobar	27 Participants n=274 Participants	24 Participants n=276 Participants	8 Participants n=142 Participants	59 Participants n=692 Participants
Right bundle branch block	39 Participants n=274 Participants	36 Participants n=276 Participants	22 Participants n=142 Participants	97 Participants n=692 Participants
Heart rate, bpm	107.2 beats per minute STANDARD_DEVIATION 17.1 • n=274 Participants	111.6 beats per minute STANDARD_DEVIATION 20.2 • n=276 Participants	108.9 beats per minute STANDARD_DEVIATION 17.2 • n=142 Participants	109.3 beats per minute STANDARD_DEVIATION 18.5 • n=692 Participants
Respiratory rate, rpm	22.2 respirations per minute STANDARD_DEVIATION 6.7 • n=274 Participants • Data unavailable for 1 subject in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm and 1 subject in the non-randomized cohort.	22.4 respirations per minute STANDARD_DEVIATION 5.9 • n=275 Participants • Data unavailable for 1 subject in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm and 1 subject in the non-randomized cohort.	23.1 respirations per minute STANDARD_DEVIATION 6.7 • n=141 Participants • Data unavailable for 1 subject in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm and 1 subject in the non-randomized cohort.	22.5 respirations per minute STANDARD_DEVIATION 6.4 • n=690 Participants • Data unavailable for 1 subject in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm and 1 subject in the non-randomized cohort.
Systolic blood pressure at diagnosis, mmHg	134.0 mmHg STANDARD_DEVIATION 22.4 • n=274 Participants • Data unavailable for 1 subject in the non-randomized cohort.	132.1 mmHg STANDARD_DEVIATION 21.7 • n=276 Participants • Data unavailable for 1 subject in the non-randomized cohort.	127.7 mmHg STANDARD_DEVIATION 23.7 • n=141 Participants • Data unavailable for 1 subject in the non-randomized cohort.	132.0 mmHg STANDARD_DEVIATION 22.5 • n=691 Participants • Data unavailable for 1 subject in the non-randomized cohort.
Diastolic blood pressure at diagnosis, mmHg	83.8 mmHg STANDARD_DEVIATION 14.7 • n=274 Participants • Data unavailable for 1 subject in the non-randomized cohort.	84.1 mmHg STANDARD_DEVIATION 14.7 • n=276 Participants • Data unavailable for 1 subject in the non-randomized cohort.	80.0 mmHg STANDARD_DEVIATION 14.6 • n=141 Participants • Data unavailable for 1 subject in the non-randomized cohort.	83.2 mmHg STANDARD_DEVIATION 14.8 • n=691 Participants • Data unavailable for 1 subject in the non-randomized cohort.
mMRC dyspnea score Score 0 - Dyspnea only with strenuous exercise	16 Participants n=271 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 4 subjects in the non-randomized cohort.	12 Participants n=273 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 4 subjects in the non-randomized cohort.	9 Participants n=138 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 4 subjects in the non-randomized cohort.	37 Participants n=682 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 4 subjects in the non-randomized cohort.
mMRC dyspnea score Score 1 - Dyspnea when hurrying or walking up a slight hill	23 Participants n=271 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 4 subjects in the non-randomized cohort.	17 Participants n=273 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 4 subjects in the non-randomized cohort.	5 Participants n=138 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 4 subjects in the non-randomized cohort.	45 Participants n=682 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 4 subjects in the non-randomized cohort.
mMRC dyspnea score Score 2 - Walks slower than people of same age due to dyspnea or has to stop for breath when walking	37 Participants n=271 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 4 subjects in the non-randomized cohort.	39 Participants n=273 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 4 subjects in the non-randomized cohort.	13 Participants n=138 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 4 subjects in the non-randomized cohort.	89 Participants n=682 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 4 subjects in the non-randomized cohort.
mMRC dyspnea score Score 3 - Stops for breath after walking 100 yards (91 m) or after a few minutes	87 Participants n=271 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 4 subjects in the non-randomized cohort.	79 Participants n=273 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 4 subjects in the non-randomized cohort.	36 Participants n=138 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 4 subjects in the non-randomized cohort.	202 Participants n=682 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 4 subjects in the non-randomized cohort.
mMRC dyspnea score Score 4 - Too dyspneic to leave house or breathless when dressing	108 Participants n=271 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 4 subjects in the non-randomized cohort.	126 Participants n=273 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 4 subjects in the non-randomized cohort.	75 Participants n=138 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 4 subjects in the non-randomized cohort.	309 Participants n=682 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 4 subjects in the non-randomized cohort.
NYHA classification Class I - No limitation of physical activity	26 Participants n=272 Participants • Data unavailable for 2 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 3 subjects in the non-randomized cohort.	19 Participants n=273 Participants • Data unavailable for 2 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 3 subjects in the non-randomized cohort.	13 Participants n=139 Participants • Data unavailable for 2 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 3 subjects in the non-randomized cohort.	58 Participants n=684 Participants • Data unavailable for 2 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 3 subjects in the non-randomized cohort.
NYHA classification Class II - Slight limitation of physical activity	54 Participants n=272 Participants • Data unavailable for 2 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 3 subjects in the non-randomized cohort.	51 Participants n=273 Participants • Data unavailable for 2 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 3 subjects in the non-randomized cohort.	11 Participants n=139 Participants • Data unavailable for 2 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 3 subjects in the non-randomized cohort.	116 Participants n=684 Participants • Data unavailable for 2 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 3 subjects in the non-randomized cohort.
RV function on echocardiogram Moderately reduced	42 Participants n=178 Participants • Only subjects with RV function collected at both the Baseline and 24 Hour Visit are reported here, resulting in unavailable data for 96 subjects in the RCT FlowTriever cohort, 105 subjects in the RCT CDT cohort, and 62 subjects in the non-randomized cohort.	41 Participants n=171 Participants • Only subjects with RV function collected at both the Baseline and 24 Hour Visit are reported here, resulting in unavailable data for 96 subjects in the RCT FlowTriever cohort, 105 subjects in the RCT CDT cohort, and 62 subjects in the non-randomized cohort.	19 Participants n=80 Participants • Only subjects with RV function collected at both the Baseline and 24 Hour Visit are reported here, resulting in unavailable data for 96 subjects in the RCT FlowTriever cohort, 105 subjects in the RCT CDT cohort, and 62 subjects in the non-randomized cohort.	102 Participants n=429 Participants • Only subjects with RV function collected at both the Baseline and 24 Hour Visit are reported here, resulting in unavailable data for 96 subjects in the RCT FlowTriever cohort, 105 subjects in the RCT CDT cohort, and 62 subjects in the non-randomized cohort.
NYHA classification Class III - Marked limitation of physical activity	122 Participants n=272 Participants • Data unavailable for 2 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 3 subjects in the non-randomized cohort.	127 Participants n=273 Participants • Data unavailable for 2 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 3 subjects in the non-randomized cohort.	58 Participants n=139 Participants • Data unavailable for 2 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 3 subjects in the non-randomized cohort.	307 Participants n=684 Participants • Data unavailable for 2 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 3 subjects in the non-randomized cohort.
NYHA classification Class IV - Unable to carry on any physical activity without discomfort	70 Participants n=272 Participants • Data unavailable for 2 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 3 subjects in the non-randomized cohort.	76 Participants n=273 Participants • Data unavailable for 2 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 3 subjects in the non-randomized cohort.	57 Participants n=139 Participants • Data unavailable for 2 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 3 subjects in the non-randomized cohort.	203 Participants n=684 Participants • Data unavailable for 2 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 3 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 3 subjects in the non-randomized cohort.
Modified Borg dyspnea score	3.12 units on a scale STANDARD_DEVIATION 2.63 • n=274 Participants • Data unavailable for 2 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm and 7 subjects in the non-randomized cohort.	3.32 units on a scale STANDARD_DEVIATION 2.58 • n=274 Participants • Data unavailable for 2 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm and 7 subjects in the non-randomized cohort.	3.93 units on a scale STANDARD_DEVIATION 2.96 • n=135 Participants • Data unavailable for 2 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm and 7 subjects in the non-randomized cohort.	3.36 units on a scale STANDARD_DEVIATION 2.69 • n=683 Participants • Data unavailable for 2 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm and 7 subjects in the non-randomized cohort.
RV/LV ratio (CTPA or echocardiogram)	1.27 ratio STANDARD_DEVIATION 0.26 • n=262 Participants • Data unavailable for 12 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 16 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 14 subjects in the non-randomized cohort.	1.31 ratio STANDARD_DEVIATION 0.27 • n=260 Participants • Data unavailable for 12 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 16 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 14 subjects in the non-randomized cohort.	1.31 ratio STANDARD_DEVIATION 0.33 • n=128 Participants • Data unavailable for 12 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 16 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 14 subjects in the non-randomized cohort.	1.29 ratio STANDARD_DEVIATION 0.28 • n=650 Participants • Data unavailable for 12 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 16 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 14 subjects in the non-randomized cohort.
RV function on echocardiogram Normal	1 Participants n=178 Participants • Only subjects with RV function collected at both the Baseline and 24 Hour Visit are reported here, resulting in unavailable data for 96 subjects in the RCT FlowTriever cohort, 105 subjects in the RCT CDT cohort, and 62 subjects in the non-randomized cohort.	0 Participants n=171 Participants • Only subjects with RV function collected at both the Baseline and 24 Hour Visit are reported here, resulting in unavailable data for 96 subjects in the RCT FlowTriever cohort, 105 subjects in the RCT CDT cohort, and 62 subjects in the non-randomized cohort.	2 Participants n=80 Participants • Only subjects with RV function collected at both the Baseline and 24 Hour Visit are reported here, resulting in unavailable data for 96 subjects in the RCT FlowTriever cohort, 105 subjects in the RCT CDT cohort, and 62 subjects in the non-randomized cohort.	3 Participants n=429 Participants • Only subjects with RV function collected at both the Baseline and 24 Hour Visit are reported here, resulting in unavailable data for 96 subjects in the RCT FlowTriever cohort, 105 subjects in the RCT CDT cohort, and 62 subjects in the non-randomized cohort.
RV function on echocardiogram Mildly reduced	13 Participants n=178 Participants • Only subjects with RV function collected at both the Baseline and 24 Hour Visit are reported here, resulting in unavailable data for 96 subjects in the RCT FlowTriever cohort, 105 subjects in the RCT CDT cohort, and 62 subjects in the non-randomized cohort.	11 Participants n=171 Participants • Only subjects with RV function collected at both the Baseline and 24 Hour Visit are reported here, resulting in unavailable data for 96 subjects in the RCT FlowTriever cohort, 105 subjects in the RCT CDT cohort, and 62 subjects in the non-randomized cohort.	3 Participants n=80 Participants • Only subjects with RV function collected at both the Baseline and 24 Hour Visit are reported here, resulting in unavailable data for 96 subjects in the RCT FlowTriever cohort, 105 subjects in the RCT CDT cohort, and 62 subjects in the non-randomized cohort.	27 Participants n=429 Participants • Only subjects with RV function collected at both the Baseline and 24 Hour Visit are reported here, resulting in unavailable data for 96 subjects in the RCT FlowTriever cohort, 105 subjects in the RCT CDT cohort, and 62 subjects in the non-randomized cohort.
RV function on echocardiogram Severely reduced	122 Participants n=178 Participants • Only subjects with RV function collected at both the Baseline and 24 Hour Visit are reported here, resulting in unavailable data for 96 subjects in the RCT FlowTriever cohort, 105 subjects in the RCT CDT cohort, and 62 subjects in the non-randomized cohort.	119 Participants n=171 Participants • Only subjects with RV function collected at both the Baseline and 24 Hour Visit are reported here, resulting in unavailable data for 96 subjects in the RCT FlowTriever cohort, 105 subjects in the RCT CDT cohort, and 62 subjects in the non-randomized cohort.	56 Participants n=80 Participants • Only subjects with RV function collected at both the Baseline and 24 Hour Visit are reported here, resulting in unavailable data for 96 subjects in the RCT FlowTriever cohort, 105 subjects in the RCT CDT cohort, and 62 subjects in the non-randomized cohort.	297 Participants n=429 Participants • Only subjects with RV function collected at both the Baseline and 24 Hour Visit are reported here, resulting in unavailable data for 96 subjects in the RCT FlowTriever cohort, 105 subjects in the RCT CDT cohort, and 62 subjects in the non-randomized cohort.
Parenteral anticoagulation use at baseline UFH and/or LMWH: Total	261 Participants n=274 Participants	267 Participants n=276 Participants	135 Participants n=142 Participants	663 Participants n=692 Participants
Parenteral anticoagulation use at baseline UFH and/or LMWH: UFH	221 Participants n=274 Participants	236 Participants n=276 Participants	120 Participants n=142 Participants	577 Participants n=692 Participants
Parenteral anticoagulation use at baseline UFH and/or LMWH: LMWH	25 Participants n=274 Participants	24 Participants n=276 Participants	10 Participants n=142 Participants	59 Participants n=692 Participants
Parenteral anticoagulation use at baseline UFH and/or LMWH: UFH and LMWH	15 Participants n=274 Participants	7 Participants n=276 Participants	5 Participants n=142 Participants	27 Participants n=692 Participants
Parenteral anticoagulation use at baseline Another parenteral agent	0 Participants n=274 Participants	1 Participants n=276 Participants	0 Participants n=142 Participants	1 Participants n=692 Participants
Parenteral anticoagulation use at baseline None	13 Participants n=274 Participants	8 Participants n=276 Participants	7 Participants n=142 Participants	28 Participants n=692 Participants
Time from study hospital presentation to treatment catheter insertion, hours	22.3 hours STANDARD_DEVIATION 17.7 • n=271 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 5 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 3 subjects in the non-randomized cohort.	24.9 hours STANDARD_DEVIATION 19.7 • n=271 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 5 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 3 subjects in the non-randomized cohort.	38.3 hours STANDARD_DEVIATION 62.8 • n=139 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 5 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 3 subjects in the non-randomized cohort.	26.6 hours STANDARD_DEVIATION 33.4 • n=681 Participants • Data unavailable for 3 subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm, 5 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm, and 3 subjects in the non-randomized cohort.
mPAP, mmHg	30.0 mmHg STANDARD_DEVIATION 7.6 • n=274 Participants • Data unavailable for 6 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm and 1 subject in the non-randomized cohort.	31.1 mmHg STANDARD_DEVIATION 7.2 • n=270 Participants • Data unavailable for 6 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm and 1 subject in the non-randomized cohort.	29.7 mmHg STANDARD_DEVIATION 7.5 • n=141 Participants • Data unavailable for 6 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm and 1 subject in the non-randomized cohort.	30.4 mmHg STANDARD_DEVIATION 7.4 • n=685 Participants • Data unavailable for 6 subjects in the Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm and 1 subject in the non-randomized cohort.

PRIMARY outcome

Timeframe: Hospital discharge or at 7 days after the index procedure, whichever is sooner

Population: Enrolled subjects in the Randomized Controlled Trial Cohort - FlowTriever Arm and Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm were assessed for this Outcome Measure.

Outcome measures

Outcome measures
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=276 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm n=274 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
Primary Endpoint: Composite Clinical Endpoint Constructed as a 5-Component Win Ratio	10509 Number of Wins for the group	—	52693 Number of Wins for the group

SECONDARY outcome

Timeframe: Hospital discharge or at 7 days after the index procedure, whichever is sooner

This secondary endpoint is a composite constructed as a hierarchical win ratio of the following 4 components: * All-cause mortality, or * Intracranial hemorrhage (ICH), or * Major bleeding per ISTH definition, or * Clinical deterioration defined by hemodynamic or respiratory worsening, and/or escalation to a bailout therapy A win ratio larger than 1 indicates that patients who receive treatment with FlowTriever are more likely to have better outcomes as compared to subjects treated with CDT.

Outcome measures

Outcome measures
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=276 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm n=274 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
Composite Clinical Endpoint Constructed as a 4-Component Win Ratio	5912 Number of Wins for the group	—	7925 Number of Wins for the group

SECONDARY outcome

Timeframe: Hospital discharge or at 7 days after the index procedure, whichever is sooner

Population: All enrolled subjects

Outcome measures

Outcome measures
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=276 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=142 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm n=274 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
All-cause Mortality	1 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Hospital discharge or at 7 days after the index procedure, whichever is sooner

Population: All enrolled subjects with available outcome

Outcome measures

Outcome measures
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=275 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=142 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm n=274 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
Intracranial Hemorrhage (ICH)	1 Participants	0 Participants	2 Participants

SECONDARY outcome

Timeframe: Hospital discharge or at 7 days after the index procedure, whichever is sooner

Population: All enrolled subjects

Outcome measures

Outcome measures
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=276 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=142 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm n=274 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
Major Bleeding Per ISTH Definition	19 Participants	10 Participants	19 Participants

SECONDARY outcome

Timeframe: Hospital discharge or at 7 days after the index procedure, whichever is sooner

Population: All enrolled subjects

Clinical deterioration is defined as documented objective hemodynamic or respiratory worsening that is new (i.e. not present at the time of enrollment). Bailout therapy is an unplanned escalation of therapeutic measures, taken when the patient's condition has not improved or is not improving according to expectations.

Outcome measures

Outcome measures
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=276 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=142 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm n=274 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
Clinical Deterioration Defined by Hemodynamic or Respiratory Worsening, and/or Escalation to a Bailout Therapy	15 Participants	5 Participants	5 Participants

SECONDARY outcome

Timeframe: Hospital discharge or at 7 days after the index procedure, whichever is sooner

Population: All enrolled subjects

Outcome measures

Outcome measures
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=276 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=142 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm n=274 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
ICU Admission During the Index Hospitalization and Following the Index Procedure	272 Participants	65 Participants	114 Participants

SECONDARY outcome

Timeframe: Hospital discharge or at 7 days after the index procedure, whichever is sooner

Population: All enrolled subjects with available outcome

Outcome measures

Outcome measures
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=272 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=65 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm n=114 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
ICU Length of Stay During the Index Hospitalization and Following the Index Procedure Among Subjects With ICU Admission. ICU length of stay 0-24 hours	94 Participants	30 Participants	61 Participants
ICU Length of Stay During the Index Hospitalization and Following the Index Procedure Among Subjects With ICU Admission. ICU length of stay >24 hours	178 Participants	35 Participants	53 Participants

SECONDARY outcome

Timeframe: 30 days from index procedure

Population: All enrolled subjects with available outcome

Outcome measures

Outcome measures
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=240 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=127 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm n=251 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
All Cause Mortality	2 Participants	5 Participants	1 Participants

SECONDARY outcome

Timeframe: 30 days from index procedure

Population: All enrolled subjects with available outcome

Outcome measures

Outcome measures
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=239 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=124 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm n=251 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
All-cause and PE-related Readmissions PE-related readmission	2 Participants	1 Participants	0 Participants
All-cause and PE-related Readmissions All-cause readmission	19 Participants	13 Participants	8 Participants

SECONDARY outcome

Timeframe: Through the 30 day visit

Population: All enrolled subjects with available outcome

Device-related SAEs included those adjudicated by the CEC to be related to the interventional device.

Outcome measures

Outcome measures
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=240 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=123 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm n=254 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
Device-related Serious Adverse Events	12 Participants	9 Participants	19 Participants

SECONDARY outcome

Timeframe: Through the 30 day visit

Population: All enrolled subjects with available outcome

Drug-related SAEs included those adjudicated by the CEC to be related to anticoagulation and/or thrombolytics medication.

Outcome measures

Outcome measures
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=244 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=123 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm n=254 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
Drug-related Serious Adverse Events	28 Participants	18 Participants	31 Participants

SECONDARY outcome

Timeframe: Hospital discharge or at 7 days after the index procedure, whichever is sooner

Population: All enrolled subjects with available outcome

Outcome measures

Outcome measures
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=275 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=142 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm n=274 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
Clinically Relevant Non-Major (CRNM) and Minor Bleeding Events Clinically relevant non-major (CRNM) bleeding events	9 Participants	6 Participants	7 Participants
Clinically Relevant Non-Major (CRNM) and Minor Bleeding Events Minor bleeding events	1 Participants	0 Participants	6 Participants

SECONDARY outcome

Timeframe: Baseline to 24 hour visit

Population: All enrolled subjects with available outcome

Assessments of change were made using the same imaging modality at baseline and at the 24-hour visit.

Outcome measures

Outcome measures
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=259 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=127 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm n=259 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
Change in Right-ventricular/Left-ventricular (RV/LV) Ratio, as Measured by Echocardiography or CT	-0.30 ratio Standard Deviation 0.26	-0.38 ratio Standard Deviation 0.29	-0.32 ratio Standard Deviation 0.24

SECONDARY outcome

Timeframe: At 24 hour visit

Population: All enrolled subjects with available outcome

The mMRC score is reported on a 0-4 scale with lower scores representing less dyspnea.

Outcome measures

Outcome measures
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=250 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=130 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm n=259 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
Modified Medical Research Council (mMRC) Dyspnea Score at 24 Hour Visit Score 0 - Dyspnea only with strenuous exercise	77 Participants	40 Participants	80 Participants
Modified Medical Research Council (mMRC) Dyspnea Score at 24 Hour Visit Score 1 - Dyspnea when hurrying or walking up a slight hill	54 Participants	35 Participants	83 Participants
Modified Medical Research Council (mMRC) Dyspnea Score at 24 Hour Visit Score 2 - Walks slower than people of the same age due to dyspnea or stops for breath when walking	53 Participants	29 Participants	61 Participants
Modified Medical Research Council (mMRC) Dyspnea Score at 24 Hour Visit Score 3 - Stops for breath after walking 100 yards (91 m) or after a few minutes	44 Participants	21 Participants	27 Participants
Modified Medical Research Council (mMRC) Dyspnea Score at 24 Hour Visit Score 4 - Too dyspneic to leave house or breathless when dressing	22 Participants	5 Participants	8 Participants

SECONDARY outcome

Timeframe: At 30 day visit

Population: All enrolled subjects with available outcome

The mMRC score is reported on a 0-4 scale with lower scores representing less dyspnea.

Outcome measures

Outcome measures
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=254 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=121 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm n=258 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
Modified Medical Research Council (mMRC) Dyspnea Score at 30 Day Visit Score 0 - Dyspnea only with strenuous exercise	138 Participants	60 Participants	137 Participants
Modified Medical Research Council (mMRC) Dyspnea Score at 30 Day Visit Score 1 - Dyspnea when hurrying or walking up a slight hill	63 Participants	33 Participants	74 Participants
Modified Medical Research Council (mMRC) Dyspnea Score at 30 Day Visit Score 2 - Walks slower than people of the same age due to dyspnea or stops for breath when walking	27 Participants	17 Participants	28 Participants
Modified Medical Research Council (mMRC) Dyspnea Score at 30 Day Visit Score 3 - Stops for breath after walking 100 yards (91 m) or after a few minutes	23 Participants	6 Participants	14 Participants
Modified Medical Research Council (mMRC) Dyspnea Score at 30 Day Visit Score 4 - Too dyspneic to leave house or breathless when dressing	3 Participants	5 Participants	5 Participants

SECONDARY outcome

Timeframe: Through 30 days post-procedure

Population: All enrolled subjects

Outcome measures

Outcome measures
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=276 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=142 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm n=274 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
Length of Total Hospital Stay	5.3 hospital overnights Standard Deviation 3.9	7.8 hospital overnights Standard Deviation 7.4	4.5 hospital overnights Standard Deviation 2.8

SECONDARY outcome

Timeframe: Through 30 days post-procedure

Population: All enrolled subjects

Outcome measures

Outcome measures
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=276 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=142 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm n=274 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
Length of Post-index-procedure Hospital Stay	4.0 days Standard Deviation 3.71	5.4 days Standard Deviation 5.80	3.2 days Standard Deviation 2.72

SECONDARY outcome

Timeframe: At 30 day visit

Population: All enrolled subjects with available outcome

The Pulmonary Embolism Quality of Life (PEmb-QOL) questionnaire is used to assess the quality of life in patients with pulmonary embolism (PE). It is a disease-specific tool designed to evaluate the impact of PE on various aspects of a patient's life, including daily activities, work, social life, and emotional well-being, and is reported on a 0-100 scale with lower scores representing better quality of life.

Outcome measures

Outcome measures
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=253 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=123 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm n=260 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
Pulmonary Embolism Quality of Life (PEmb-QOL) Score at 30 Day Visit	20.42 score on a scale Standard Deviation 19.95	23.50 score on a scale Standard Deviation 21.75	19.33 score on a scale Standard Deviation 18.91

SECONDARY outcome

Timeframe: At 30 day visit

Population: All enrolled subjects with available outcome

Each of the five dimensions comprising the EQ-5D-5L descriptive system (mobility, self-care, usual activates, pain/discomfort, anxiety/depression) are graded from 1 (no problems) to 5 (extreme problems). A descriptive health state is defined by combining each level for 5 dimensions into a 5-digit code (e.g., 12345) which is then mapped to the health state index score based on a country-specific value set. Health state index scores range from less than 0 (where 0 is the value of a health state equivalent to dead; negative values representing values as worse than dead) to 1 (the value of full health).

Outcome measures

Outcome measures
Measure	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=255 Participants Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=123 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - FlowTriever Arm n=259 Participants Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
EQ-5D-5L Quality of Life Score at 30 Day Visit	0.817 score on a scale Standard Deviation 0.237	0.742 score on a scale Standard Deviation 0.284	0.829 score on a scale Standard Deviation 0.218

Adverse Events

Randomized Controlled Trial Cohort - FlowTriever Arm

Serious events: 43 serious events

Other events: 23 other events

Deaths: 3 deaths

Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm

Serious events: 47 serious events

Other events: 18 other events

Deaths: 2 deaths

Non-Randomized Absolute Contraindication to Thrombolytics Cohort

Serious events: 35 serious events

Other events: 13 other events

Deaths: 6 deaths

Serious adverse events

Other adverse events

Additional Information

Ashleigh Willson

Inari Medical

Phone: 925-330-3446

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Restriction type: LTE60

Serious adverse events
Measure	Randomized Controlled Trial Cohort - FlowTriever Arm n=274 participants at risk Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=276 participants at risk Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=142 participants at risk Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
Vascular disorders Deep vein thrombosis	0.73% 2/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Hypotension	0.73% 2/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	1.1% 3/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Syncope	0.73% 2/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Abdominal wall haematoma	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Cerebral haemorrhage	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Haematoma	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Cerebrovascular accident	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	1.4% 2/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Heparin-induced thrombocytopenia	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Postmenopausal haemorrhage	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Pulmonary embolism	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	1.4% 4/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Chest wall haematoma	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Presyncope	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Embolic stroke	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Gangrene	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Haematoma muscle	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Haemorrhage	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Hypertensive emergency	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Iliac artery occlusion	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Shock haemorrhagic	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Thrombosis	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Injury, poisoning and procedural complications Vascular access site haematoma	2.6% 7/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	2.5% 7/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Injury, poisoning and procedural complications Vascular access site haemorrhage	1.1% 3/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Injury, poisoning and procedural complications Post procedural haemorrhage	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Injury, poisoning and procedural complications Vascular pseudoaneurysm	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Injury, poisoning and procedural complications Catheter site haematoma	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Injury, poisoning and procedural complications Orbital haemorrhage	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Injury, poisoning and procedural complications Postoperative wound infection	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Injury, poisoning and procedural complications Procedural hypotension	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Blood and lymphatic system disorders Anaemia	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	3.5% 5/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Blood and lymphatic system disorders Blood loss anaemia	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	2.1% 3/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Blood and lymphatic system disorders Iron deficiency anaemia	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Blood and lymphatic system disorders Normocytic anaemia	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Blood and lymphatic system disorders Thrombocytopenia	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Blood and lymphatic system disorders Leukocytosis	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Cardiac disorders Dyspnoea	0.73% 2/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Cardiac disorders Atrial fibrillation	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Cardiac disorders Cardiac arrest	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Cardiac disorders Atrial flutter	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Cardiac disorders Bradycardia	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Cardiac disorders Cardiac failure chronic	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.

Other adverse events
Measure	Randomized Controlled Trial Cohort - FlowTriever Arm n=274 participants at risk Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.	Randomized Controlled Trial Cohort - Catheter-Directed Thrombolysis Arm n=276 participants at risk Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system).	Non-Randomized Absolute Contraindication to Thrombolytics Cohort n=142 participants at risk Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
Injury, poisoning and procedural complications Vascular access site haemorrhage	2.2% 6/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Injury, poisoning and procedural complications Vascular access site haematoma	1.1% 3/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Injury, poisoning and procedural complications Wound	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.73% 2/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.73% 2/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Respiratory, thoracic and mediastinal disorders Non-small cell lung cancer	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Respiratory, thoracic and mediastinal disorders Pulmonary mass	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Respiratory, thoracic and mediastinal disorders Respiratory distress	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.72% 2/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Cardiac disorders Bradycardia	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Cardiac disorders Cardiogenic shock	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Cardiac disorders Ventricular tachycardia	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Cardiac disorders Arrhythmia	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Cardiac disorders Atrial fibrillation	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Cardiac disorders Pericardial effusion	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.72% 2/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Cardiac disorders Supraventricular tachycardia	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Cardiac disorders Tricuspid valve incompetence	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Gastrointestinal disorders Ascites	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Gastrointestinal disorders Colitis	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Gastrointestinal disorders Pharyngo-oesophageal diverticulum	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Infections and infestations Pneumonia	0.73% 2/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Infections and infestations Urinary tract infection	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Infections and infestations Endocarditis	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Infections and infestations Infection	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Haematoma	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Orthostatic hypotension	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Cerebrovascular accident	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
General disorders Swelling face	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Vascular disorders Epistaxis	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
General disorders Necrosis	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
General disorders Oedema peripheral	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Investigations Right ventricular systolic pressure decreased	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Investigations Haemoglobin decreased	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Investigations Oxygen saturation decreased	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Investigations Respiratory rate increased	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.36% 1/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Investigations Transaminases increased	0.00% 0/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.70% 1/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.
Psychiatric disorders Mental status changes	0.36% 1/274 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/276 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.	0.00% 0/142 • Adverse events collected from time of enrollment through 30 Day visit or study exit, if exited early. For European subjects, reporting began after signing informed consent, while US subjects reporting began after the study device entered the vasculature. The All-Cause Mortality field reports all deaths reported through study exit and from vital status tracing after exit (including cases of sponsor awareness after exit), differing slightly from the 30-day all-cause mortality secondary endpoint. All CEC adjudicated events (all SAEs and non-serious AEs potentially related to a primary/secondary endpoint reported prior to study exit) as well as non-adjudicated events known from vital status tracing in subjects lost to follow-up are listed here. Mortality status is known at the earlier of study exit or day 30 for everyone except 2 RCT subjects lost to follow-up. The all-cause mortality rate excluding these subjects is 1.1% (3/273) for the FlowTriever arm and 0.7% (2/275) for the CDT arm.